These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 38630860)
1. Design of dry powder inhalers to improve patient outcomes: it's not just about the device. Weers JG Expert Opin Drug Deliv; 2024 Mar; 21(3):365-380. PubMed ID: 38630860 [TBL] [Abstract][Full Text] [Related]
2. Dry powder inhalers in COPD, lung inflammation and pulmonary infections. Muralidharan P; Hayes D; Mansour HM Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926 [TBL] [Abstract][Full Text] [Related]
3. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers. Grant AC; Walker R; Hamilton M; Garrill K J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466 [TBL] [Abstract][Full Text] [Related]
4. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™). Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465 [TBL] [Abstract][Full Text] [Related]
5. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver. Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109 [TBL] [Abstract][Full Text] [Related]
6. The clinical relevance of dry powder inhaler performance for drug delivery. Demoly P; Hagedoorn P; de Boer AH; Frijlink HW Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253 [TBL] [Abstract][Full Text] [Related]
7. Dry powder inhalation: past, present and future. de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143 [TBL] [Abstract][Full Text] [Related]
9. A review of co-milling techniques for the production of high dose dry powder inhaler formulation. Lau M; Young PM; Traini D Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654 [TBL] [Abstract][Full Text] [Related]
10. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients. Darbà J; Ramírez G; Sicras A; Francoli P; Torvinen S; Sánchez-de la Rosa R Int J Chron Obstruct Pulmon Dis; 2015; 10():2335-45. PubMed ID: 26604733 [TBL] [Abstract][Full Text] [Related]
11. The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers. Weers J; Clark A Pharm Res; 2017 Mar; 34(3):507-528. PubMed ID: 27738953 [TBL] [Abstract][Full Text] [Related]
12. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients. Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137 [TBL] [Abstract][Full Text] [Related]
13. Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes. Levy ML; Carroll W; Izquierdo Alonso JL; Keller C; Lavorini F; Lehtimäki L Adv Ther; 2019 Oct; 36(10):2547-2557. PubMed ID: 31478131 [TBL] [Abstract][Full Text] [Related]
14. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler. Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467 [TBL] [Abstract][Full Text] [Related]
15. The dry powder inhaler features of the Easyhaler that benefit the management of patients. Chrystyn H; Lavorini F Expert Rev Respir Med; 2020 Apr; 14(4):345-351. PubMed ID: 32013627 [No Abstract] [Full Text] [Related]
16. Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study. Zervas E; Samitas K; Gaga M Int J Chron Obstruct Pulmon Dis; 2016; 11():1845-55. PubMed ID: 27540287 [TBL] [Abstract][Full Text] [Related]
17. Building respirable powder architectures: utilizing polysaccharides for precise control of particle morphology for enhanced pulmonary drug delivery. Kadota K; Uchiyama H; Kämäräinen T; Tanaka S; Tozuka Y Expert Opin Drug Deliv; 2024 Jun; 21(6):945-963. PubMed ID: 38961522 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099 [TBL] [Abstract][Full Text] [Related]